BioWorld

Dec. 15, 2004

Corixa Sells Bexxar To GSK, Cuts Staff By 160 Employees

With slower-than-expected sales growth of Bexxar, Corixa Corp. decided to turn worldwide rights for the non-Hodgkin's lymphoma product over to partner GlaxoSmithKline plc. (BioWorld Today) Read More

Genitope Stock Sale: $53.7M To Fund Manufacturing, More

Cutting Off TB's Energy Source Might Be Novel Line Of Attack

Inex Cuts Nearly Two-Thirds Of Staff, Plans New Marqibo Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...